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822 The Journal of Thoracic and CardioObjectives: We sought to determine the effect of cardiopulmonary bypass and
surgical intervention on the natriuretic hormone system in children and to assess
whether such changes are associated with morbidity.
Methods: At 6 perioperative time points in 25 patients, plasma levels of atrial
natriuretic peptide, brain natriuretic peptide, and guanosine 3=, 5=-monophosphate
were measured, and the biologic activity of the natriuretic hormone system was
quantified. Relationships were sought between changes in brain natriuretic peptide
levels, biologic activity, and a number of morbidity indicators.
Results: There was a significant change in atrial natriuretic peptide levels (P 
.037), brain natriuretic peptide levels (P  .001), and biologic activity of the
natriuretic hormone system (P  .009) over the first 4 time points in the study.
Atrial natriuretic peptide levels transiently decreased from baseline to 12 hours after
surgical intervention. Compared with baseline values, brain natriuretic peptide
levels were increased at 12 hours after surgical intervention and on postoperative
day 1. The increase in brain natriuretic peptide levels from baseline to 12 hours after
surgical intervention was associated with cardiopulmonary bypass time (rs  0.4, P
 .047). The biologic activity transiently decreased from baseline to intensive care
unit admission but was not associated with any morbidity indicators.
Conclusions: Increased postoperative brain natriuretic peptide levels are associated
with longer bypass times. The biologic activity of the natriuretic hormone system is
transiently impaired. Larger studies should investigate brain natriuretic peptide as a
predictor of postoperative morbidity and the potential for natriuretic hormone
infusions to improve postoperative hemodynamics and urine output.
T he natriuretic hormone system (NHS) plays an important role in the regula-tion of vascular tone and fluid balance in healthy children and adults and inthose with hemodynamically significant cardiac disease.1-4 However, little is
known about the acute effects of cardiopulmonary bypass (CPB) and surgical
intervention on the NHS or whether such an effect might have an impact on the
postoperative course.
The objective of our ongoing research initiative is to determine the role of the
NHS in the regulation of vascular resistance and fluid balance in infants, children,
and young adults after CPB. The primary hypothesis of this study is that the
calculated biologic activity of the NHS would decrease after CPB. We also hypoth-
esized that plasma atrial natriuretic peptide (ANP) levels would decrease and brain
natriuretic peptide (BNP) levels would increase in the early postoperative period,
perhaps reflective of postoperative alterations in atrial stretch, volume load, and
ventricular function. Finally, we sought to determine whether changes in the
biologic activity of the NHS and BNP levels are associated with intraoperative and
postoperative variables that predict early morbidity.
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Patient Selection
The Institutional Review Board of Children’s Memorial Hospital
approved the study, and written informed consent was obtained
from the patients, their parents or guardians, or both. This pro-
spective, single-center, observational study enrolled 25 patients
from the following prospectively defined surgical subgroups: com-
plete repair of intracardiac left-to-right shunt with congestive heart
failure (CHF); Norwood operation; bidirectional Glenn (BDG)
operation; extracardiac Fontan completion; and Fontan revision.
These 5 operations are commonly performed in our institution
using standardized surgical techniques. In a prior report, we de-
scribed perioperative changes in the NHS in 5 infants with intra-
cardiac left-to-right shunting and CHF.5 In the current study we
sought to determine whether similar changes were present after
other pediatric operations that result in reduction in atrial stretch or
ventricular volume load. These surgical subgroups were also se-
lected because of the risk for postoperative fluid retention and
increased vascular resistance.
Surgical Repair
The intracardiac repair, Norwood operation, BDG operation, and
extracardiac, nonfenestrated Fontan operations were performed
with standardized surgical techniques. Indications for revision of
Fontan circulation include refractory atrial arrhythmias and ana-
tomic obstruction of the Fontan pathway. The revision operation
typically consists of conversion from an atriopulmonary Fontan
connection to an extracardiac total cavopulmonary connection,
wide right atrial wall excision with systematic cryoablation of the
remaining atrial tissue (either a modified right-sided maze or Cox
maze III), and permanent atrial pacemaker placement. Operative
anesthetic management and CPB strategy followed a standard
institutional protocol. Regional perfusion techniques were used to
minimize the duration of circulatory arrest during the Norwood
and Fontan revision procedures. All patients received aprotinin and
dexamethasone intraoperatively. Modified ultrafiltration was used
after CPB in 17 of 25 patients.
Assay of Natriuretic Peptides
Blood was obtained from each patient’s arterial catheter at the
following time points: baseline (after induction of general anes-
thesia and before sternotomy), 30 minutes after arrival to the
intensive care unit (ICU) after surgical intervention, 12 hours after
surgical intervention, and during the morning of postoperative
days (PODs) 1, 2, and 3. Blood was placed in prechilled vacuum
tubes containing 0.068 mL of 7.5% (K3) ethylenediamine tetraace-
tic acid and immediately processed on ice. The tubes were placed
in a refrigerated centrifuge, and the supernatant plasma was placed
in aliquots in polystyrene tubes and frozen at 70°C. The plasma
samples were sent to a reference laboratory (Cardiorenal Research
Laboratory, Mayo Clinic, Rochester, Minn) for measurement of
ANP, BNP, and their secondary messenger, guanosine 3=, 5=-
monophosphate (cGMP), using standardized radioimmunoassay
techniques. The biologic activity of the NHS was determined at
each time point by calculating the molar ratio of cGMP/(ANP 
BNP). The following molar weights were used in these calcula-
tions: ANP, 3078 g/mol; BNP, 3462 g/mol. Normal adult natri-
uretic hormone values as reported by the reference laboratory were
The Journal of Thoraciused for patients older than 16 years as follows: ANP, 25  11
pg/mL; BNP, 12  4 pg/ml. Reference levels for infants and
children were as follows: at birth, ANP of 129  77 pg/mL and
BNP of 197  170 pg/mL; 5 days old, ANP of 120  62 pg/mL
and BNP of 62  14 pg/mL; less than 4 months old, ANP of 49
 15 pg/mL and BNP of 21  10 pg/mL; less than 1 year old,
ANP of 49  9 pg/mL and BNP of 7  7 pg/mL; less than 5 years
old, ANP of 25  12 pg/mL and BNP of 7  3 pg/mL; less than 10
years old, ANP of 28  9 pg/mL and BNP of 7 3 pg/mL; less than
16 years old, ANP of 31  12 pg/mL and BNP of 7  3 pg/mL.6
At each time point, the following clinical indicators that might
predict postoperative morbidity were determined. Arterial venous
oxygen saturation difference was calculated by oxyhemoglobin
measurements from the arterial catheter and distal superior vena
cava (or from the BDG or Fontan pathways in those surgical
subsets). The cardiac index was calculated with the Fick equation
by using assumed oxygen consumption. Arterial lactate levels
were measured with amperometry (ABL 700 Series Analyzers;
Radiometer Medical A/S, Bronshoi, Denmark). An inotrope score
was calculated as follows (all doses in g · kg1 · min1):
Inotrope score  [Dopamine  Dobutamine
 (Milrinone  10)  (Epinephrine  100)].
CPB and aortic crossclamp times and days of postoperative
ICU stay were recorded for each patient. The subjects’ preopera-
tive clinical characteristics and operative and postoperative
courses were prospectively recorded.
Statistics
Statistical analysis was performed with SPSS version 10.0.5 (SPSS,
Inc, Chicago, Ill). Continuous variables were reported as medians
(intraquartile ranges), except where otherwise indicated. Because
plasma samples were unavailable for a number of subjects on PODs
2 and 3, differences in natriuretic hormone levels and biologic activity
were explored for the first 4 time points only by using the Friedman
test. If an overall statistically significant difference was found, indi-
vidual time points were compared with baseline by the Wilcoxon
signed-rank test with a Bonferroni correction. The strength of the
relationship between continuous variables was estimated by the
Spearman rank correlation coefficient. Descriptive terms were used to
discuss results for the surgical subgroups because small patient num-
bers preclude statistical analysis.
Results
Subjects
Twenty-seven consecutive patients were eligible for the
study during the enrollment period, and written informed
consent was obtained from 25 patients. Patient demographic
data and operative procedures are listed in Table 1. Two of
the 25 patients did not have a central venous catheter in the
superior vena cava, and thus arterial venous oxygen satura-
tion difference and cardiac index were not calculated (pa-
tients 15 and 24).
Natriuretic Hormone Levels and Biologic Activity
When compared with normal values for age, baseline ANP
levels were increased in all of the intracardiac left-to-right
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Dshunt patients and 3 of 5 patients in both the Norwood and
BDG subgroups (Table 2). Baseline ANP levels were nor-
mal in all of the patients undergoing the extracardiac Fontan
procedure and in 4 of 5 patients undergoing Fontan revision.
There was a significant change in ANP levels for the whole
study group over the first 4 time points in the study (n 25,
P  .037). ANP levels transiently decreased from baseline
to 12 hours after the operation (Figure 1, A). When com-
pared with baseline values, ANP levels at 12 hours after
surgical repair were consistently lower in the intracardiac
shunt subset. A similar trend was noted in the other sub-
groups: 4 of 5 ANP levels were lower at 12 hours compared
with baseline values in the Norwood, BDG, and extracar-
diac Fontan subgroups, and 4 of 5 ANP levels were lower
TABLE 1. Subject diagnoses, operations, and preoperative
Patient
no. Lesion Age (y) Last operation Preo
Intracardiac repair
2 CAVC, CHF 0.45 None Mild 2
3 IAVC, CHF 4.04 None Moder
4 VSD, CHF 0.50 None Norma
10 VSD, CHF 0.36 None Norma
11 VSD, CHF 0.54 None Norma
Norwood operation
6 HLHS 0.01 None Norma
8 Unbl CAVC, CoA 0.01 None Norma
15 HLHS 0.01 None Norma
16 HLHS 0.02 None Norma
23 HLHS 0.01 None Norma
Bidirectional Glenn operation
18 TA 0.58 MBTS Norma
21 DILV/TGA/CoA 0.55 Norwood Mild 2
22 DORV/TGA/PS 3.13 None Norma
24 TA 0.42 MBTS Norma
25 HLHS 0.54 Norwood/Sano Norma
Extracardiac Fontan
13 HLHS 3.47 BDG Mild 2
14 HLHS 2.82 BDG Mild 2
17 DORV/TGA/PS 3.17 BDG Norma
19 DILV/TGA/CoA 3.19 BDG Norma
20 PA/IVS 3.44 BDG Norma
Fontan revision
1 DILV/TGA 19.38 RAA-PA Fontan Moder
5 TA 17.41 RAA-PA Fontan Norma
7 TA 14.53 RAA-PA Fontan Norma
9 DILV/TGA 26.68 LT Fontan Norma
12 TA 21.58 RAA-PA Fontan Mild 2
Preoperative Ftn, preoperative systemic ventricular function; CPB, cardiopu
CHF, congestive heart failure; IAVC, incomplete atrioventricular canal;
unbalanced; CoA, coarctation of aorta; TA, tricuspid atresia; MBTS, mo
ventricle; TGA, transposition of great vessels; DORV, double-outlet right ven
septum; RAA-PA, right atrial appendage to pulmonary artery; CMIII, Cox
ventricular angiography. †Reported as median (range).than baseline values on POD 1 in the Fontan revision group.
824 The Journal of Thoracic and Cardiovascular Surgery ● SeptBaseline BNP levels, when compared with normal values
for age, were increased in 4 of 5 patients receiving intra-
cardiac shunts and 3 of 5 patients undergoing the Norwood
procedure (the same 3 patients who had increased ANP
levels, Table 2). In contrast, 13 of 15 baseline BNP levels
were normal in patients in the BDG, extracardiac Fontan,
and Fontan revision subgroups. For the patients in the BDG,
extracardiac Fontan, and Fontan revision subgroups who
had a preoperative cardiac catheterization, systemic ventric-
ular end-diastolic pressure ranged from 5 to 14 mm Hg,
which was associated with baseline BNP levels (n  14,
Spearman’s rho  0.69, P  .006). There was a significant
change in BNP levels over the first 4 time points in the study
(n  25, P  .001). Compared with baseline values, BNP
tricular function
Operation CPB time (min)† ACX time (min)†
94 (72-118) 67 (46-76)
CAVC repair
IAVC repair
VSD repair
VSD repair
VSD repair
149 (120-186) 55 (49-59)
Norwood
Norwood
Norwood/Sano
Norwood/Sano
Norwood/Sano
106 (77-140) None
BDG
BDG
BDG
BDG
BDG
37 (27-76) 0 (0-6)
Extracardiac Fontan
Extracardiac Fontan
Extracardiac Fontan
Extracardiac Fontan
Extracardiac Fontan
201 (120-243) 48 (16-79)
Fontan revision/CMIII
Fontan revision
Fontan revision
Fontan revision/CMIII
Fontan revision
ry bypass; ACX, aortic crossclamp; CAVC, complete atrioventricular canal;
ventricular septal defect; HLHS, hypoplastic left heart syndrome; Unbl,
Blalock-Taussig shunt; BDG, bidirectional Glenn; DILV, double-inlet left
; PS, pulmonary stenosis; PA/IVS, pulmonary atresia with intact ventricular
e III; LT, lateral tunnel. *Determined by means of echocardiography orven
p Ftn*
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Dand on POD 1 (Figure 1, B). Figure 2 illustrates the changes
in BNP levels over time for the Norwood subgroup. A
similar trend of increasing BNP levels was seen in the other
surgical subgroups because 3 of 5 BNP levels were higher
at 12 hours after surgical intervention compared with base-
line values in the intracardiac repair and extracardiac Fontan
groups, 4 of 5 BNP levels were higher at 12 hours compared
with baseline values in the Fontan revision group, and 5 of
5 BNP levels were higher at 12 hours compared with
baseline values in the BDG group (Table 2).
There was no significant change in plasma cGMP con-
centrations over the first 4 time points in the study (n  22,
P  .44, Figure 1, C). There was a significant change in the
biologic activity of the NHS over the first 4 time points in
the study (n  21, P  .009). Biologic activity transiently
decreased from baseline to ICU admission (Figure 3). Sim-
ilar trends were found in each of the surgical subgroups,
with the exception of the patients with CHF undergoing
intracardiac repair (data not shown).
A positive association was found between the change in
BNP levels for the whole study group from baseline to 12
hours after surgical intervention and CPB time (n  25,
Spearman’s rho 0.4, P .047). Similar trends were noted
between the change in BNP levels from baseline to 12 hours
after surgical intervention and aortic crossclamp time (P 
.066) and arterial lactate levels 12 hours after surgical
intervention (P  .058). These findings were clearly influ-
enced by data from the 5 patients undergoing the Norwood
operation, and removal of these patients from the analysis
weakens the relationships. No significant association was
found between the change in BNP levels from baseline to 12
hours after surgical intervention and cardiac index or ino-
tropic score at that time point or days of postoperative ICU
stay. No significant association was found between the
change in NHS biologic activity from baseline to ICU
TABLE 2. Natriuretic hormone levels for surgical subgrou
Operation Baseline ICU admit
Intracardiac repair ANP 164 (63-339) 62 (51-108)
BNP 91 (4-301) 69 (9-230)
Norwood ANP 337 (65-521) 243 (51-340)
BNP 208 (28-413) 360 (169-586)
BDG ANP 71 (34-82) 94 (14-118)
BNP 14 (4-21) 29 (18-67)
Extracardiac Fontan ANP 24 (9-54) 58 (12-135)
BNP 8 (4-37) 23 (4-37)
Fontan revision ANP 47 (22-123) 64 (14-77)
BNP 22 (19-54) 32 (19-84)
ICU, Intensive care unit; POD, postoperative day; ANP, atrial natriuretic pep
peptide and brain natriuretic peptide levels are presented in picograms padmission and any of the clinical indicators.
The Journal of ThoraciDiscussion
Natriuretic hormones bind to dedicated receptors in the
vascular endothelium, myocardium, and kidneys, which ac-
tivate guanylyl cyclase, leading to production of cGMP.
cGMP-dependent protein kinases act on several intracellular
substrates to reduce cytosolic calcium and cause smooth and
cardiac myocyte relaxation.7 In the kidney natriuretic hor-
mones promote diuresis directly by causing afferent arterio-
lar vasodilation and efferent arteriolar vasoconstriction,
which increases the glomerular filtration rate.8 Natriuretic
hormones indirectly augment urine output by inhibiting the
effects of the sympathetic nervous system and angiotensin II
on proximal tubular sodium absorption, blunting aldoste-
rone production, and inhibiting vasopressin’s effect at the
medullary collecting duct.9 The NHS has diagnostic, prog-
nostic, and therapeutic utility in adults with CHF.1,10,11
Predictable increases in natriuretic hormone levels occur in
children with congenital heart defects.2-4 Because several of
the pathophysiologic features encountered in CHF mimic
those seen after CPB, including neurohumoral activation,
myocardial dysfunction, increased vascular resistance, and
fluid retention, it is intuitively attractive to investigate the
NHS in the immediate postoperative period in infants and
children.
The results of this study suggest that important changes
in the NHS occur in infants and children who are exposed to
CPB during the course of cardiac surgical repair or pallia-
tion. The observation that ANP levels transiently decreased
postoperatively might be mechanistically explained by re-
duction of atrial stretch and volume overload, as has been
proposed in adults after mitral valvuloplasty.12 In the intra-
cardiac shunt group the large left-to-right shunt was elimi-
nated after surgical intervention, and the observed decrease
in ANP levels is similar to that seen in prior reports by our
group and other investigators.5,13 Infants with hypoplastic
left heart syndrome typically experience significant pulmo-
12 h POD 1 POD 2 POD 3
57 (16-79) 56 (30-90) 131 (68-263) 133 (112-188)
24 (59-846) 63 (15-880) 118 (41-722) 94 (60-138)
67 (55-260) 129 (66-509) 137 (123-259) 144 (80-171)
62 (261-543) 403 (170-603) 275 (65-521) 95 (33-131)
37 (12-63) 28 (15-77) 58 (27-85) 65 (42-105)
48 (31-212) 75 (34-136) 54 (27-66) 46 (10-65)
9 (6-28) 37 (16-85) 62 (34-97) 69 (18-102)
32 (5-51) 17 (6-75) 33 (22-90) 22 (8-56)
51 (26-88) 16 (12-117) 65 (20-130) 50 (2-220)
53 (34-203) 33 (20-185) 35 (26-106) 56 (24-253)
BNP, brain natriuretic peptide; BDG, bidirectional Glenn. *Atrial natriuretic
lliliter. Data are reported as median (range).ps*
1
1
4
tide;nary overcirculation because their pulmonary vascular re-
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after the Norwood procedure, a more balanced circulation is
present because of fixed obstruction provided by the pul-
monary shunt. The BDG operation provides a substantial
reduction of volume load to the heart. In contrast to the
Figure 1. A, ANP levels over time for all study patients. B, BNP
levels over time for all study patients. C, cGMP levels over time
for all study patients (*significant difference vs baseline).atriopulmonary Fontan procedure, which has been associ-
826 The Journal of Thoracic and Cardiovascular Surgery ● Septated with an increase in ANP levels, this study and others
have documented either unchanged or decreasing ANP lev-
els after the extracardiac Fontan procedure.14,15 The subse-
quent increase in ANP levels for the whole study group on
PODs 1 through 3 is difficult to explain, but potential causes
include ANP production by the ventricular myocardium or
impaired clearance of ANP by natriuretic peptide clearance
Figure 2. Change in BNP levels over time for the patients under-
going a Norwood operation. Three of the 5 patients had increased
preoperative BNP levels for age, likely reflective of a significant
volume overload of the single ventricle. Patients 8, 15, 16, and 23,
all of whom required an epinephrine infusion postoperatively,
had higher BNP levels for an extended period of time compared
with patient 6, who did not require epinephrine. Patient 8 had a
marked and sustained increase in BNP levels and died on POD 2
of neoaortic insufficiency, pulmonary hypertension, and low car-
diac output. Note that patient 15 did not have a BNP level
measured on POD 2.
Figure 3. Biologic activity over time for all study patients (*sig-
nificant difference vs baseline).receptors or neutral endopeptidases.16-18
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levels for the whole study group that was associated with
CPB times, and similar trends exist for aortic crossclamp
times and lactate levels at 12 hours after surgical interven-
tion. The increase in BNP levels might be attributable in
part to the effects of CPB and surgical manipulation on
myocardial function and wall stress. Although not formally
evaluated in this study, increasing BNP levels have a neg-
ative association with indices of myocardial function after
valvular or coronary bypass surgery in adults.19 An increase
in early postoperative BNP levels has been previously re-
ported after repair of tetralogy of Fallot and intracardiac
left-to-right shunts and after extracardiac Fontan comple-
tion.5,15 The extent of the increase in BNP levels has been
associated with longer aortic crossclamp times, with poten-
tial for myocardial ischemia-reperfusion injury in adults,
and a trend toward such an effect was seen in this study.19,20
Although no association was found between inotropic
scores and the change in BNP levels for the whole study
population, increasing BNP levels might be predictive of
the need for significant inotropic support in selected sub-
groups, as was seen in our patients undergoing the Norwood
operation (Figure 2). In the Fontan revision subgroup the
single patient who required an epinephrine infusion postop-
eratively had a marked increase in BNP levels and a pro-
longed ICU stay when compared with the other members of
this subgroup. The ability of BNP levels to predict postop-
erative morbidity and mortality requires investigation in a
larger number of similar patients.
In this study we used the molar ratio of cGMP/(ANP 
BNP) to quantify the biologic activity of the NHS. Other
investigators have reported using the molar ratio of cGMP/
ANP for this purpose.13,21 The use of a single peptide in
such calculations does not appear to be fundamentally
sound because cGMP is the secondary mediator for multiple
peptides in the natriuretic hormone family. We previously
suggested that the ratio of cGMP/(ANP  BNP  Den-
droaspis natriuretic peptide) might provide the most com-
prehensive assessment of the biologic activity of the NHS.5
In the current study, we did not measure Dendroaspis na-
triuretic peptide because levels of this peptide did not ap-
preciably change after CPB in our prior study. C-type na-
triuretic peptide and urodilitin are additional members of the
natriuretic hormone family that act in paracrine fashion
within the vascular endothelium and kidney, respec-
tively.22,23 Because C-type natriuretic peptide and urodilitin
concentrations are not increased in the plasma of adults with
CHF, these peptides were not measured during this study.
Because the biologic effects of cGMP are considered to
be a consequence of increased intracellular levels of this
messenger, the use of plasma levels of cGMP is an indirect
assessment of the biologic effects of the NHS. The ability of
natriuretic peptides to increase intracellular and extracellu-
The Journal of Thoracilar cGMP levels in vascular smooth muscle and endothelial
cell culture models is well established, and the measurement
of plasma or urine cGMP levels as a marker of endogenous
and exogenous natriuretic hormone activity has been re-
ported in a number of adult and pediatric studies.24 cGMP is
also the secondary mediator for nitric oxide, and distur-
bances in this system after CPB could influence cGMP
levels. However, plasma cGMP levels do not correlate with
nitrate and nitrite levels, markers of nitric oxide production,
in children undergoing CPB.13
The mechanism by which CPB impairs the biologic
activity of the NHS is not known, and this study was not
designed to explore this issue. The biologic activity of the
NHS in adults with severe CHF might be decreased because
of natriuretic peptide receptor downregulation or distur-
bances in postreceptor signal transduction.25 Increased
phosphodiesterase activity might decrease cGMP levels, as
has been observed in experimental CHF.26 In cell culture
models hypothermia impairs ANP receptor-ligand dissoci-
ation, which might decrease cGMP production, and cellular
egress of cGMP.24,27
Decreased biologic activity of the NHS might play a role
in the development of fluid retention and increased vascular
resistance, which typically occur after pediatric CPB. In this
study we were unable to detect any relationship between the
biologic activity of the NHS and several previously reported
measures of postoperative morbidity and mortality. How-
ever, preliminary reports suggest that the infusion of natri-
uretic peptides has favorable hemodynamic and renal ef-
fects after CPB in adults.28 In the only published pediatric
study of perioperative natriuretic hormone infusions, 8 chil-
dren after the Fontan operation received a 1-hour infusion of
ANP, resulting in increased urine output, decreased pulmo-
nary vascular resistance and central venous filling pressure,
and favorable trends in cardiac index and systemic vascular
resistance.29
Limitations
This study is limited by the small number of patients en-
rolled and the high intraindividual and interindividual vari-
ability in the NHS. Objective assessment of ventricular
function and vascular resistance would have enabled us to
determine whether relationships existed between these vari-
ables and BNP levels and NHS biologic activity. The use of
assumed oxygen consumption in the Fick equation to cal-
culate cardiac output is problematic because oxygen con-
sumption might be quite variable after CPB.30 Although we
did not measure oxygen consumption or use thermodilution
catheters to calculate cardiac output, all patients were
deeply sedated and mechanically ventilated until at least the
first postoperative day, likely making the cardiac output
measurements more reliable for a least the first 4 time points
in the study. The use of modified ultrafiltration in 17 of 25
c and Cardiovascular Surgery ● Volume 130, Number 3 827
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natriuretic peptides and cGMP might be eliminated across
the filtration membrane. During a previous investigation,5
we measured levels of natriuretic peptides and cGMP in the
ultrafiltrate collected from 5 infants who had undergone
conventional ultrafiltration during rewarming on CPB fol-
lowed by 10 minutes of modified ultrafiltration (unpub-
lished data). Median ultrafiltrate ANP levels were 2118
pg/mL (range, 708-2603 pg/mL), approximately 6-fold
higher than simultaneous plasma levels. Median BNP levels
were 3.4 pg/mL (range, 1-4.3 pg/mL), approximately 25%
of plasma levels obtained at the same time period. Median
cGMP levels were 19.4 pmol/mL (range, 6.4-21.2 pmol/
mL), approximately twice as high as simultaneous plasma
levels. These findings might be explained by the fact that
plasma ANP and cGMP concentrations were relatively pre-
served compared with baseline values during CPB and thus
available at higher concentrations for filtration, whereas
plasma BNP levels precipitously decreased during CPB.
Conclusions
Systematic changes in natriuretic hormone levels occur after
congenital heart surgery involving CPB. Increasing BNP
levels are associated with longer CPB times. The biologic
activity of the NHS is transiently impaired in the early
postoperative period. Further investigation is warranted to
elucidate the clinical significance of these observations in
larger numbers of infants, children, and young adults un-
dergoing similar procedures and to determine whether the
use of natriuretic hormone infusions favorably affects the
postoperative course after CPB.
We thank Kimberlee Gauvreau, ScD, from the Children’s Hos-
pital Boston and Harvard Medical School for her valuable statis-
tical input.
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